The FDA recently released the results of their multi-year opioid product quality survey aimed to detect substitutions of illicit fentanyl in the supply chain of FDA-regulated opioids. The FDA reported no evidence of illegal substitution in any FDA-regulated opioids, ingredients used to make opioids, opioid overdose reversal products, and opioid use disorder (OUD) treatment products tested. Cont.
U.S. House | This week, the House Oversight and Accountability Committee held a hearing on “Oversight and Reauthorization of the Office of National Drug Control Policy." Dr. Rahul Gupta, ONDCP Directo
U.S. Senate | Last week, the Senate Appropriations Committee passed a FY24 funding bill for several priority agencies including the Substance Abuse and Mental Health Services Administration (SAMHSA),
DEA [3/22] | In a public safety alert, the DEA said it observed a sharp increase in the trafficking of fentanyl mixed with xylazine, a sedative also known as “Tranq” that has been approved by the Food